Author

N. Mendes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Oliveira· 2 shared D. Ferreira· 2 shared A. Andre· 1 shared A. Burleigh· 1 shared A. F. Vieira· 1 shared A. Ferreira· 1 shared A. Heravi-Moussavi· 1 shared A. Lopes· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

C. Oliveira

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Shifting KRAS hotspot mutations inhibition paradigm in colorectal cancer

A. R. Bras, A. Lopes, N. Mendes, P. J. Costa, A. Ferreira, S. Granja, A. P. Silva, F. Tortosa, F. Baltazar, F. Gartner, M. J. Sousa, A. Valente, A. Preto

This study identifies a ruthenium compound, PMC79, that selectively inhibits KRAS mutations in colorectal cancer and enhances chemotherapy efficacy.

bioRxiv · Aug 9, 2023 · PreprintPharmacology & Toxicology

Epithelial-mesenchymal plasticity induced by discontinuous exposure to TGFβ1 promotes tumour growth

M. Santos, M. Ferreira, P. Oliveira, N. Mendes, A. Andre, A. F. Vieira, J. B. Nunes, J. Carvalho, S. Rocha, M. Azevedo, D. Ferreira, I. Reis, J. Vinagre, J. Paredes, A. Heravi-Moussavi, , C. Oliveira

The paper shows that discontinuous TGFβ1 exposure induces EMT/MET transitions in EpH4 cells, leading to RE-cells with molecular and functional heterogeneity that promotes tumour growth.

bioRxiv · Nov 2, 2021Cell Biology

CD44v6 expression is a novel predictive marker of therapy response and poor prognosis in gastric cancer patients

C. Pereira, D. Ferreira, C. Lemos, D. Martins, N. Mendes, D. Almeida, P. Granja, F. Carneiro, R. Almeida, G. M. Almeida, C. Oliveira

This study identifies CD44v6 expression as a predictor of therapy response and poor prognosis in gastric cancer patients, showing higher expression correlates with worse outcomes and benefit from chemotherapy.

bioRxiv · Nov 30, 2018 · PreprintCancer Biology